Canadian-based cannabis company TerrAscend has acquired exclusive distribution rights to Syqe Medical’s Syqe medical cannabis inhaler in Canada, the companies announced. The Syqe inhaler, which uses cartridges loaded with medical cannabis plant material, has been available to patients for the treatment of pain in Israel since June 2019; previously, the inhaler was available in Israel for hospital use only.
TerrAscend will distribute the Syqe inhaler through TerrAscend Canada and its “Online Marketplace for Licensed Producer,” Solace Health Network, which promotes a “convenient on-boarding and shopping experience.”
Syqe CEO and Founder Perry Davidson said, “Syqe’s goal since inception has been to bring relief to as many patients as possible in the fastest possible way, and we spent eight years developing the Syqe inhaler to ensure that when introduced, it would make a significant positive impact on patients’ lives. We have been searching for a partner that is truly focused on the medical side of cannabis. We are thrilled to be working with TerrAscend to share our groundbreaking technology with a progressive market at the forefront of medical cannabis treatment.”
TerrAscend CEO Michael Nashat commented, “We’ve seen time and again the deficiencies of current drug delivery devices – whether it be dosage inconsistencies or side effects – and recognize that the industry is ready to be disrupted. Syqe’s device is on the cutting edge of drug delivery technology, and we are excited to facilitate their entry into the Canadian medical cannabis market, as there is a real need for a new approach to an age-old problem.”
Read the Syqe and TerrAscend press release.
